Objectives-Cytokines, released from mononuclear cells
Abstract
Objectives-Cytokines, released from mononuclear cells (MNC) are mediators of joint destruction in rheumatoid arthritis (RA). The mechanisms of action of gold salts used in the treatment of RA are unknown. The aim of this study was to investigate cytokine expression and intensity of MNC infiltrate in the RA synovial membrane (SM) following treatment with sodium aurothiomalate (SAT). Methods-Sequential blind needle biopsies were obtained at entry into the study and at two and 12 weeks after the start of SAT therapy in 10 patients with active RA. SMs were stained with a panel of monoclonal antibodies to assess cytokine expression (IL-la, IL-1i, TNF-a, IL-6, and GM-CSF).
Results-There was a significant decrease in IL-la, IL-1i, IL-6 and TNF-a expression 12 weeks after treatment (p < 0-004, p < 0-002, p < 0009 and p < 0-004 respectively). This was noted in the lining layer, the perivascular aggregates and the connective tissue areas. Detailed examination of the MNC infiltrate showed a significant reduction in inflammatory monocytes (MONO) Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease of unknown aetiology. Its pathogenesis is predicated on T cell and MONO/MAC activation with the release of a number of monokines such as interleukin 1 (IL-1) and tumour necrosis factor alpha (TNF-ct), which secondarily lead to the release of cytokines from other cells such as synoviocytes. ' Collectively, the release of these and other inflammatory mediators as well as the activation of synoviocytes, MONOs/MACs, chondrocytes and osteoclasts bring about the inflammatory and destructive changes which are characteristic of the disease. A crucial role for these pathogenetic events is the accumulation of MONOs from the circulation. Bone marrow grafting experiments in mice have shown that the resident type A cells of the synovial lining layer are of bone marrow origin.2 After entry into tissues, MONOs mature into MACs and the differentiation steps involved have been studied in vitro and followed both in vivo and in vitro by appropriate monoclonal antibodies (mAb). Sorg et al have developed a series of monoclonal antibodies which mark the early acute inflammatory MONO (27E10)3 and the anti-inflammatory MAC (RM 3/1).4 There is increasing evidence that the function of MONO/MAC is dependent on the stage of differentiation reached by these cells. Thus MONO are potent producers of proinflammatory monokines such as IL-1, whereas optimal production of the IL-1 receptor antagonist (IL-lra) requires that the MONO be matured to MAC by in vitro culture in the presence of immobilised IgG, as a form of model immune complexes, and granulocyte/ macrophage colony stimulating factor (GM-CSF).5 6 Since inflammatory events may be regulated by the balance between proinflammatory cytokines, such as IL-1, and soluble inhibitors, such as IL-ira, the shift of this balance to the latter could offer therapeutic benefits to the patient. Indeed, IL-Ira has been shown to be effective treatment for experimental models of arthritis.7
The treatment of RA with SAT is still widespread despite a variable therapeutic response, serious side effects and lack of knowledge of its mode of action.8 Little attention has been paid to the changes which occur in the RA SM following the introduction of SAT. In previous studies, a reduction in the T-cell infiltrate was noted9 10 but only after six months of treatment by which time therapeutic benefit is well established. Other measurements of inflammatory capacity, such as decreased HLA-DR expression, decreased thickness of the synovial lining layer and reduction in the number of blood vessels, have proved equally disappointing." So called disease modifying drugs (DMARDs), such as SAT, have been used for the treatment of RA on empirical grounds; consequently, their mode of action is still uncertain and is based mainly on in vitro work. This is particularly true for SAT for which such diverse activities as inhibition of MONO accessory function in T lymphocyte activation, inhibition of production of rheumatoid factor production, interference with the antigen presenting function of HLA molecules and inhibition of endothelial cell proliferation, have been described;8 however, little or no evidence has been produced on the relevance of these findings to its in vivo mode of action. Recently, it has been shown that SAT will accelerate the in vitro maturation of MONO to MAC with a concomitant decrease in IL-1 production.'2 13 Thus there is now the possibility to relate the therapeutic benefit with changes in expression of cytokines and the relative contribution of inflammatory MONO and downregulatory MAC within the synovial cell populations.
We reasoned that if SAT could induce maturation of MONO in the RA SM then there would be decreased production of proinflammatory cytokines as well as a decrease in the numbers of 27E10 positive monocytes, the former being dependent on the latter. In this study, multiple synovial biopsies were obtained from the knee joints of patients with RA before and at two and 12 weeks following the administration of SAT. Serial changes in cellular composition, with particular reference to MONO and MAC cells, and cytokine expression were examined using immunohistochemistry with appropriate mAb directed against cellular markers and against the inflammatory cytokines IL-1, TNF-ot, GM-CSF and interleukin 6 (IL-6).
Patients and methods

PATIENTS AND TREATMENT PROTOCOL
Ten patients (table 1) with RA'4 attending the Rheumatology Unit of Guy's and Lewisham Hospitals were selected for a study comparing the clinical and synovial histological changes observed after the administration of intramuscular SAT or a combination of intramuscular SAT and methylprednisolone. All patients received intramuscular SAT which was given as a 10 mg test dose followed by 50 mg weekly until a total dose of 1-0 g was reached after which SAT was continued at 50 mg monthly. Five patients received 120 mg of methylprednisolone acetate intramuscularly at 0, 4 and 8 weeks of SAT whilst the other five received intramuscular 1 ml normal saline at the same time. Allocation between the two treatment groups was random.'5 Patients were entered into the study if they required DMARDs and had either persistent synovitis despite non-steroidal anti-inflammatory drugs Patients were assessed by one rheumatologist at entry into the study and at two and 12 weeks following the administration of SAT. Routine measurements of disease activity included Ritchie articular index,'6 visual analogue scale for pain (VAS), grip strength (using a folded sphygmanometer cuff inflated to 30 mm/Hg, three attempts and results expressed as the mean value of both hands). Laboratory assessments included full blood count, ESR in the first hour and rheumatoid factor.
SYNOVIAL BIOPSY
Synovial samples were obtained from one knee joint of all patients by a blind biopsy technique at 0, 2 and 12 weeks using a WilliamsonHolt synovial biopsy needle (Shrimpton and Fletcher Needle Industries, Redditch, Worcestershire, UK) under sterile conditions. Where only one knee was involved, the specimens were obtained from the affected side, when both knees were involved, the biopsy was performed on a side selected at random. Repeat biopsies were performed on the same knee joint. Local anaesthesia using 2% lignocaine was administered. To facilitate the biopsy procedure, 20 ml of sterile saline were instilled into each joint. Multiple synovial samples (minimum of four) were obtained from the supra-patellar pouch of the knee joint from as wide an area as possible within reach of the needle. 18 The mAb used to determine cellular content were UCHT1, OKT4, OKT8, TO15, and EBMIl (anti-CD3, anti-CD4, anti-CD8, anti-CD22 and anti-CD68 respectively, Dako laboratories, Copenhagen, Denmark), UCHM1 (anti-CD14, gift of Dr N Hogg, ICRF, London), 27E10 and RM3/1 (early MONO and late MAC markers respectively, gift of Professor C Sorg, Germany). FVIII (Dako) was used to stain endothelial cells. The mAb used to determine cytokine expression were anti-IL-lot (gift of Dr R Thorpe, NIBSC, Potters Bar), anti-IL-I ( (gift of Dr D Boraschi, Italy), anti-IL-6 (gift of Dr T Hirano, Osaka, Japan), anti-TNF-ct (gift of Dr H A Cousin, Roussel, Romainville, France) and anti-GM-CSF (gift of Dr K Ruedi, Sandoz, Basel, Switzerland).
Briefly, the primary mAbs, at appropriate dilutions in phosphate buffer saline (PBS), were incubated on synovial tissue sections in a humidified chamber at room temperature for two hours for cytokine staining and for 45 minutes for cellular antigen staining, after an initial incubation for 120 minutes with a 1:20 dilution of normal rabbit serum. The excess mAb was removed by washing with PBS. After absorption with human liver powder diluted at 1:20 in normal human serum, the second antibody, biotinylated rabbit anti-mouse IgG (Dako Laboratories, Copenhagen, Denmark) diluted in PBS at 1:300, was added and sections incubated for 30 minutes. This was followed by washing with PBS and incubation for 45 minutes with avidin-biotin peroxidase complex (ABC Vecta Stain Kit, Vector Laboratories, Ontario, Canada). The sections were developed in a solution of diaminobenzidine tetrahydrochloride (0 7 mg/ml), and counterstained with haematoxylin. Finally, sections were dehydrated by transferring through alcohol and CNP30 and mounted in DPX.
Negative control staining was performed on all synovial specimens studied. This was identical except that incubation with the primary mAb was omitted. No staining was noted in these sections. Tonsil tissue was used as a positive control. Other controls included MOPC21, a non-immune mouse IgG1 myeloma protein used at equivalent protein concentration with a similar isotype to the cytokine monoclonal antibodies used.
All comparisons between specimens were made with data derived from the same staining run.
CONFIRMATION OF CYTOKINE IMMPUNOREACTIVITY
The specificity of the cytokine monoclonal antibodies has been extensively studied and demonstrated by the providers of these proteins. Anti-TNF-ot (personal communication from MA Cousin, Roussel) (1) lining layer, (2) 12 weeks after the start of therapy compared with entry into the study (fig 1 a-f) . No changes were noted at two weeks (data not shown).
In the lining layer (fig 2) , there was a significant decrease in the intensity of staining for IL-lot from 5 0 at entry to 4X2 at 12 weeks (p < 005), IL-113 from 6-0 to 2-5 (p < 0 006) and IL-6 from 4-2 to 3-8 (p < 0 05). TNF-ot fell from 4-3 to 2-0 but this just failed to reach statistical significance (p < 0 064). There was no significant change in the percentage of positively staining cells.
In the perivascular areas (fig 3) , there was a significant decrease in the intensity of staining for IL-a from 6 8 to 5 2 (p<0.01), IL-113 from 4-1 to 2 (p<001), TNF-ot from 3 5 to 1-2 (p < 0-05) and IL-6 from 3-5 to 1-5 (p < 0 01) (fig 3) . Furthermore, there was a significant reduction in the number of IL-lot and IL-6 positively staining cells, from 12% to Number of vessels per HPF 7-3 (4 9) 8-3 (4-5) 8-6 (6-0) Lining layer thickness 8-9 (4 0) 8-7 (3 5) 7-0 (3-0) 5% (p < 0 04) and from 5% to 0 (p < 0-02) respectively (fig 3) .
In the connective tissue area (fig 4) , there was a significant decrease in the intensity of staining for IL-lot from 5-2 to 2-8 (p < 0 02), IL-113 from 3 9 to 1-5 (p<0 004), TNF-ot from 3-9 to 1 (p < 0 02), IL-6 from 3-8 to 1-8 (p < 0-05) and GM-CSF from 3-5 to 1-8 (p <0.05). Furthermore, there was a significant reduction in the number of IL-la, and IL-6 positively staining cells, from 14% to 3% (p < 0 04) and from 6% to 2% (p < 0 04) respectively.
Discussion
Ten patients with active RA were studied prospectively for 12 weeks after the introduction of SAT or a combination of SAT and intramuscular steroid therapy. SM cytokine expression and intensity of MNC infiltrate were examined at 0, 2 and 12 weeks. Clinical improvement was noted in all patients at 12 weeks.
Monokine expression (IL-Aa, IL-1, TNF-a and IL-6) was diminished at 12 weeks in most areas of the synovium. Interleukin-la staining in the synovial membrane 12 weeks after starting sodium aurothiomalate therapy (magnification x 650); (C) Interleukin-1/3 staining in the synovial membrane at entry into the study (magnification x 650); (D) Interleukin-1/3 staining in the synovial membrane 12 weeks after starting sodium aurothiomalate therapy (magnification x 650); (E) Tumour necrosis factor-a staining in the synovial membrane at entry into the study (magnification x 650); (F) Tumour necrosis factor-a staining in the synovial membrane 12 weeks after starting sodium aurothiomalate therapy (magnification x650). 49 and further contribute to the decrease in MONO/MAC numbers within the synovium.
Thus a plausible scenario for the effects of gold salts can be constructed on the basis of these in vivo and in vitro observations. Before gold therapy, CD 14+ MONOs enter the rheumatoid synovium by binding to endothelial cells. In the joint, MONOs are activated and release monokines responsible for maintaining cell viability and promoting the maturation of MONOs to MACs. In the presence of gold salts there is a decrease in the endothelial cell adhesiveness resulting in a reduction of MONO entry into the RA synovium and reduction in cytokine production. In the absence of these monokines MONO viability is not maintained and MAC numbers decrease. In addition, gold accelerates the maturation of the remaining MONOs to MACs. These mature MACs may release IL-lra and other unidentified regulators of inflammation which in turn downregulate the inflammatory response by inhibiting cytokine release.
In conclusion, the findings in this study suggest that SAT may interfere with the mechanisms responsible for persistent rheumatoid synovitis by altering MONO/MAC survival, maturation and function such as release of inflammatory monokines.
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